Jazz Pharmaceuticals (NASDAQ:JAZZ) Announces Quarterly Earnings Results

Jazz Pharmaceuticals (NASDAQ:JAZZ) released its quarterly earnings results on Monday. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.05) by $0.17, FiscalAI reports. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.21 billion. During the same period in the previous year, the company posted $8.13 EPS. The business’s quarterly revenue was up 10.4% compared to the same quarter last year.

Here are the key takeaways from Jazz Pharmaceuticals’ conference call:

• Positive Sentiment: Jazz reported record third-quarter revenue of $1.24 billion, up 10% year over year, and raised 2026 revenue guidance to $4.775 billion–$4.85 billion. The company cited broad commercial execution across sleep, oncology and international markets while keeping operating-expense guidance unchanged.
• Positive Sentiment: Ziihera’s launch in first-line HER2-positive metastatic gastroesophageal adenocarcinoma generated $21 million in third-quarter sales and showed strong early community adoption, including a threefold increase in new ordering accounts in September. Jazz estimates a 3,000–4,000-patient annual U.S. addressable population and increased Ziihera’s peak-sales potential to $3 billion–$5 billion.
• Positive Sentiment: Xywav sales rose 12% to $483 million, with approximately 425 net patient additions during the quarter. Management said high-sodium oxybate generics have had limited impact so far and expects Xywav’s low-sodium profile and clinical differentiation to support continued durability into 2027.
• Positive Sentiment: Jazz completed its $820 million acquisition of Actio Biosciences, adding ABS-1230, a precision epilepsy therapy targeting KCNT1 mutations. Initial patient efficacy data are expected this quarter, while the company also advanced its orexin-2 agonist JZP269 into a Phase I trial.
• Negative Sentiment: Zepzelca faces a likely competitive headwind in 2027 from Amgen’s IMDELLTRA following strong first-line maintenance small-cell lung cancer data, although management expects no impact to 2026 guidance. Modeyso revenue growth may also proceed at a more measured pace as Jazz expands from academic centers into community oncology ahead of the ACTION trial readout in the first half of 2027.

Jazz Pharmaceuticals Stock Down 0.7%

JAZZ stock opened at $214.44 on Tuesday. The business’s 50-day moving average price is $231.16 and its 200-day moving average price is $216.50. The stock has a market cap of $13.92 billion, a P/E ratio of 14.79, a PEG ratio of 0.41 and a beta of 0.38. The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. Jazz Pharmaceuticals has a twelve month low of $128.80 and a twelve month high of $266.38.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Canaccord Genuity Group set a $300.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, August 26th. TD Cowen upped their target price on shares of Jazz Pharmaceuticals from $275.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. The Goldman Sachs Group began coverage on shares of Jazz Pharmaceuticals in a research report on Thursday, September 24th. They issued a “buy” rating and a $337.00 price target on the stock. Morgan Stanley dropped their price target on shares of Jazz Pharmaceuticals from $322.00 to $314.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 21st. Finally, UBS Group boosted their price objective on shares of Jazz Pharmaceuticals from $315.00 to $337.00 and gave the company a “buy” rating in a research report on Friday, September 11th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $292.05.

Insider Activity

In other Jazz Pharmaceuticals news, EVP Neena Patil sold 1,200 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $240.94, for a total transaction of $289,128.00. Following the sale, the executive vice president owned 47,671 shares in the company, valued at approximately $11,485,850.74. This trade represents a 2.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Robert Iannone sold 76,921 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $249.70, for a total transaction of $19,207,173.70. Following the transaction, the executive vice president directly owned 65,686 shares in the company, valued at $16,401,794.20. This represents a 53.94% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 94,121 shares of company stock valued at $23,337,922. 4.10% of the stock is owned by insiders.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz reported third-quarter revenue of approximately $1.24 billion, up 10.4% year over year and above the $1.21 billion analyst estimate. The company’s adjusted loss of $3.88 per share was narrower than the expected $4.05 loss. Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Management raised its full-year 2026 revenue outlook to roughly $4.78 billion-$4.85 billion, above the $4.73 billion consensus estimate. The increase reflects continued commercial execution across the portfolio. Jazz Pharmaceuticals 2026 Revenue Guidance
• Positive Sentiment: Xywav revenue increased 12% year over year, with 425 net patient additions during the quarter. The launch of Ziihera in first-line HER2-positive metastatic gastroesophageal adenocarcinoma also creates a potential long-term growth driver, with projected peak sales of $3 billion-$5 billion. Ziihera Launch and 2026 Guidance
• Neutral Sentiment: Jazz completed its Actio acquisition, adding the rare-epilepsy candidate ABS-1230 (JZP6979) to its pipeline. The deal expands the company’s development portfolio but introduces integration and development execution risks. Third-Quarter Financial Results
• Neutral Sentiment: Jazz will present Phase 3 ACTION trial progress and other neuro-oncology research at the Society for Neuro-Oncology meeting on November 12-15, potentially providing additional pipeline catalysts. Jazz Neuro-Oncology Research
• Negative Sentiment: The quarter’s loss contrasts sharply with $8.13 per share of earnings a year earlier. Investors may also be focused on an Actio-related charge and whether revenue growth can remain strong as the company absorbs acquisition costs and ramps Ziihera.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.